Ken Griffin Applied Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.35 - $8.5 $48,284 - $94,350	11,100 Added 140.51%	19,000 $161,000
Q2 2024 Aug 14, 2024	BUY	$4.04 - $6.37 $3,232 - $5,096	800 Added 11.27%	7,900 $36,000
Q1 2024 May 15, 2024	SELL	$2.25 - $7.4 $15,525 - $51,060	-6,900 Reduced 49.29%	7,100 $48,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $25,576 - $46,565	13,900 Added 13900.0%	14,000 $46,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.77 $630 - $1,385	-500 Reduced 83.33%	100 $0
Q2 2023 Aug 14, 2023	BUY	$0.77 - $1.8 $462 - $1,080	600 New	600 $0
Q4 2022 Feb 14, 2023	BUY	$0.54 - $1.12 $54 - $112	100 New	100 $0

140

112M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $42.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.